Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Athlon Energy Inc. (NYSE: ATHL) shares increased 2.21 percent to close at $28.17 a share Monday. The stock traded between $26.67 and $28.49 on volume of 1.11 million shares traded. Analysts at Miller Tabak have recently downgraded the company’s rating to "hold" from "buy".
Find out more about Athlon Energy including full access to the free equity report at:
www.RDInvesting.com/ATHL
EQT Midstream Partners LP (NYSE: EQM) shares decreased 1.36 percent to close at $46.99 a share Monday. The stock traded between $46.78 and $49.20 on volume of 191,999 shares traded. Analysts at Ladenburg Thalmann have recently initiated coverage on the company with a "buy" rating. Shares of EQT Midstream Partners have gained approximately 25.0 percent year-to-date.
Find out more about EQT Midstream Partners including full access to the free equity report at:
www.RDInvesting.com/EQM
Portland General Electric Company (NYSE: POR) shares declined 2.08 percent to close at $31.05 a share Monday. The stock traded between $30.78 and $31.68 on volume of 1.45 million shares traded. Analysts at DA Davidson have recently downgraded the company’s rating to "neutral" from "buy". Shares of Portland General Electric have gained approximately 13.5 percent year-to-date.
Find out more about Portland General Electric including full access to the free equity report at:
www.RDInvesting.com/POR
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) shares declined 2.08 percent to close at $31.05 a share Monday. The stock traded between $30.78 and $31.68 on volume of 1.45 million shares traded. Analysts at Cantor Fitzgerald have recently downgraded the company’s rating to "hold" from "buy". Shares of Portland General Electric have gained approximately 13.5 percent year-to-date.
Find out more about Salix Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/SLXP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com